Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate

Aptorum Group Limited APM announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.
Specifically, two additional cohorts (Cohort C & D) of the single ascending dose portion of the Phase 1 trial in healthy subjects have been completed with no serious adverse events observed.
No subjects were dropped out of the studies, and no serious adverse events were observed.
Additionally, no clinically relevant changes regarding vital signs, electrocardiogram, clinical laboratory test results and physical examinations were observed compared to baselines.
The single ascending dose is still ongoing to gain additional insights into the effect of food on bioavailability and pharmacokinetics.
On this basis, the company plans to proceed to the multiple ascending dose part in 3Q of 2021.
In May, the company completed two initial cohorts of the single-dose ascending dose portion of the Phase 1 trial.
Price Action: APM shares are up 4.64% at $3.16 during the premarket session on the last check Monday.